Cancer biotech Synthorx prices upsized IPO at $11 midpoint

Shutterstock photo

Synthorx, a preclinical biotech developing immunotherapies for solid tumors, raised $131 million by offering 11.9 million shares at $11, the midpoint of the $10 to $12 range. The company offered additional shares to raise 31% more than anticipated. Insiders had indicated on buying up to $75 million of the IPO (57%).

Synthorx plans to list on the Nasdaq under the symbol THOR. Jefferies, Leerink Partners and Evercore ISI acted as lead managers on the deal.

The article Cancer biotech Synthorx prices upsized IPO at $11 midpoint originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines , IPOs

More from Renaissance Capital


Renaissance Capital

Renaissance Capital


Research Brokers before you trade

Want to trade FX?